Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity - Wikidata - awgldk - TriplyDB

Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity

Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity

http://www.wikidata.org/entity/Q37286656

about

Cancer-Associated Myeloid Regulatory Cells Perspectives on reprograming cancer-associated dendritic cells for anti-tumor therapies The Yin and Yang of Toll-like receptors in cancer Delivery of gene silencing agents for breast cancer therapy Stimulating antitumor immunity with nanoparticles Safety of Nanoparticles in Medicine A role for the chemokine receptor CCR6 in mammalian sperm motility and chemotaxis Cytokines as biomarkers of nanoparticle immunotoxicity State-of-the-art of regulatory dendritic cells in cancer ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis Anti-tumor immunity: myeloid leukocytes control the immune landscape Pathological mobilization and activities of dendritic cells in tumor-bearing hosts: challenges and opportunities for immunotherapy of cancer Targeting abnormal ER stress responses in tumors: A new approach to cancer immunotherapy Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin Efficacy of ampicillin against methicillin-resistant Staphylococcus aureus restored through synergy with branched poly(ethylenimine)Development of nanoscale approaches for ovarian cancer therapeutics and diagnostics Lipidoid Nanoparticles Containing PD-L1 siRNA Delivered In Vivo Enter Kupffer Cells and Enhance NK and CD8(+) T Cell-mediated Hepatic Antiviral Immunity.Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like Receptor agonists as a treatment for melanoma.CD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells.The interplay between surfaces and soluble factors define the immunologic and angiogenic properties of myeloid dendritic cells.Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.Small interfering RNA targeted to IGF-IR delays tumor growth and induces proinflammatory cytokines in a mouse breast cancer model Transforming growth factor β-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression The role of microRNAs in ovarian cancer CD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells.Gene carriers and transfection systems used in the recombination of dendritic cells for effective cancer immunotherapy.Anti-radiation damage effect of polyethylenimine as a toll-like receptor 5 targeted agonist.Nanomolecular targeting of dendritic cells for ovarian cancer therapy.Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes Gold nanoparticle delivery of modified CpG stimulates macrophages and inhibits tumor growth for enhanced immunotherapy Age-related macular degeneration and the other double helix. The Cogan Lecture.Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation.Nanoparticle preconditioning for enhanced thermal therapies in cancer PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.Sustained small interfering RNA delivery by mesoporous silicon particles IL12B expression is sustained by a heterogenous population of myeloid lineages during tuberculosis.Toll-like receptors as novel therapeutic targets for ovarian cancer.Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer.Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.

P2860

Q26750382-B773E955-0273-4C99-B6CB-C9BB2BC05C8B Q26830839-90226D98-F2BE-4424-9404-2BB76BE5D974 Q26851526-B0393ECC-9AD9-40BD-A0E4-651B43B0F540 Q27008706-766CA21A-C7D1-4F45-81EC-896EE06F46EF Q27027780-03EAF062-99C5-4AFB-AA3F-B678076F6DBC Q28083076-B832886E-0EF5-41E1-9AB3-4CE01CF940AC Q28115830-8B412A39-8E4C-4CBE-9766-5CA65E0A74DD Q28383550-1E85D970-E7BA-4666-BE93-CD164311BD84 Q28383942-FC533C45-F843-4865-A839-7FE04233EF5F Q28389316-DB5614F2-45E2-48CE-8834-D5E37DD5810C Q28390573-DF3B1142-4F5F-45A1-8193-CEE24D93BB86 Q28392626-1AB80228-0DC2-47B6-90D0-EB9B9440D746 Q28392706-10553608-D1D9-40ED-A867-D05FEC70B50A Q28537820-17545425-AB9B-4BB0-815A-2AEB47D0B93D Q28821040-4B461255-934F-47B8-AEC8-06075B4D489B Q30421664-9895EC2F-AB87-4AB8-BE91-7AFF4A75300F Q30422001-7BAD8537-86D1-436E-AA52-5D9CCB38C389 Q33509292-B9E7BE86-3373-4AAC-9B1B-D454049065E3 Q33867018-7B779944-ABBE-4AEB-9B3D-9CAB61EFA6CC Q33924531-F568CCCE-7CB5-4C9F-8A1F-A4D1F9488C0C Q33926200-35E79307-B8BF-4204-ADE5-276AB912A353 Q34047394-98C6BCCE-4D30-4BCA-B2AE-F86CE0AF6BE6 Q34123598-FF255EB9-3E57-4F83-B174-173378E74CB1 Q34240499-F4812055-6A54-43F4-B00B-6CBF96DDD244 Q34253436-699000A9-D211-495B-9ACA-5354E74DC3FB Q34352531-1B3F11C9-AC2E-4653-8365-5C2748200830 Q34443707-090F61EE-A0D4-4D84-B641-D218F4D6D4FC Q34459013-1FC27720-3EEB-4881-BF26-FAE5FED79909 Q34663940-400AE13D-83A1-42EF-A6DE-B3779F8B34E5 Q34664957-92DF2C2D-83B6-489D-9130-1781E57F6553 Q34730651-0CBE4126-3647-4332-BAAF-369ABEEF2CD2 Q34824054-8CE3A4CA-2876-43DA-81CD-B27CA4EC6BFA Q34944118-3A125E2E-C657-4C7D-B1F5-4C5CAEBF9E83 Q34987068-D54C88B3-FF97-467E-96D4-D12946DE59C5 Q35107110-996921C6-64A6-430A-A4D7-3ADEF851EAE1 Q35456065-48262B10-8496-4CAE-B30C-1C105C390E24 Q35551021-7C09C603-BA9C-4315-A8A3-BECF66AC3C02 Q35864309-821C4C22-054B-419E-8B44-F9D897FCCB72 Q35871752-E05D05CC-6CEF-4306-A897-8EDF1C0D554B Q35896426-E3B4B5E7-FD22-4F42-8D73-EF9554D76B8D

P2860

Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity

http://www.wikidata.org/entity/Q37286656

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 13 July 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Polyethylenimine-based siRNA n ...... therapeutic antitumor immunity

@en

Polyethylenimine-based siRNA n ...... herapeutic antitumor immunity.

@nl

type

label

Polyethylenimine-based siRNA n ...... therapeutic antitumor immunity

@en

Polyethylenimine-based siRNA n ...... herapeutic antitumor immunity.

@nl

prefLabel

Polyethylenimine-based siRNA n ...... therapeutic antitumor immunity

@en

Polyethylenimine-based siRNA n ...... herapeutic antitumor immunity.

@nl

P1433

Q37286656-A42DB6E6-2A8F-4AA3-BA05-286ABDF771C0

P1476

Q37286656-F018DDC1-9838-4638-BB07-EC775E2029F3

P2093

Q37286656-00BF754D-A1BD-4933-8F3B-EA014E4440B1

Q37286656-07CD54C1-7917-4871-9534-500C522BA79B

Q37286656-3DBED68E-EE3B-4B74-B289-A7510F17AC4C

Q37286656-6053A139-34EB-435E-9F95-4888A55DD2EA

Q37286656-6DB5084D-58B1-47F0-9B88-00627C059462

Q37286656-7C5B1EEA-9E92-43F7-A68F-E523B175256D

Q37286656-9EFA8233-6B13-4AAF-A483-9CA6D0C546B7

Q37286656-AD660EBD-A378-413F-85F4-E6DC72648FCE

Q37286656-B5EEDC03-0029-41F1-9D31-9CAFCA724EC1

Q37286656-D4296C2B-7C6C-4624-A22A-FCA4BC67AA7F

P2860

Q37286656-02974A44-34AA-4BEE-A4F8-C7EB875A9A1F

Q37286656-03F3E12E-F86F-4AE5-85D9-A9F71EC96587

Q37286656-196780A3-6F6B-4004-8816-C1E4FB3F0BDF

Q37286656-2017AB01-5211-4129-B45D-018633AA9FA7

Q37286656-229424A7-576D-4646-8389-27F3C0646BF4

Q37286656-23E7BFF5-8299-4ADF-B51B-8FBA68B7590E

Q37286656-269A9AEF-E57B-4F8B-BE66-6CD4E194CFD4

Q37286656-3582A034-9AF0-4C0E-9F31-DC96464E8730

Q37286656-36A1E88E-7597-4C07-A952-C29FBA19BCB7

Q37286656-37CBB2A2-006F-4EDE-8DB0-E784C67130AF

P304

Q37286656-940B46FC-A72A-4275-BE18-98E64CDC68F6

P31

Q37286656-17566FB3-59ED-4269-BFDD-0B0FBE94A20A

P356

Q37286656-E11543E9-51D4-4527-9EB1-D13F4A99FDCD

P407

Q37286656-1425AC43-7806-429A-BA46-4DAAFB4D112A

P433

Q37286656-25B51085-9CDD-42D7-8504-4C3C032263B2

P478

Q37286656-70E9D5E7-58F6-4305-88BE-303238E12EA9

P577

Q37286656-72C829DF-2165-4CAD-85EE-00F6A1C25B66

P5875

Q37286656-FBAAC461-032D-4EC5-B5A1-59FEFBFA7388

P698

Q37286656-C1DBECAA-01B9-4591-9280-616170104E10

P921

Q37286656-B7E9678D-7752-483F-A4D2-6B206CF1837F

P932

Q37286656-0F867B98-5229-4EE4-9195-839B57B2B341

P356

P1433

Journal of Clinical Investigation

P1476

Polyethylenimine-based siRNA n ...... therapeutic antitumor immunity

@en

P2093

Amorette Barber

http://www.w3.org/2001/XMLSchema#string

Andrew T Gewirtz

http://www.w3.org/2001/XMLSchema#string

Charles L Sentman

http://www.w3.org/2001/XMLSchema#string

Diana Martinez

http://www.w3.org/2001/XMLSchema#string

Jose R Conejo-Garcia

http://www.w3.org/2001/XMLSchema#string

Juan R Cubillos-Ruiz

http://www.w3.org/2001/XMLSchema#string

Li Wang

http://www.w3.org/2001/XMLSchema#string

Raul Elgueta

http://www.w3.org/2001/XMLSchema#string

Ross Kedl

http://www.w3.org/2001/XMLSchema#string

Uciane K Scarlett

http://www.w3.org/2001/XMLSchema#string

P2860

Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7

Cancer statistics, 2008

PD-1 and its ligands in tolerance and immunity

Expression of programmed death 1 ligands by murine T cells and APC

Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28- antitumor T cells

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

Clinical and biological significance of tissue transglutaminase in ovarian carcinoma.

Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity.

Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma.

P304

2231-2244

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI37716

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P577

2009-07-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26684444

http://www.w3.org/2001/XMLSchema#string

P698

19620771

http://www.w3.org/2001/XMLSchema#string

P921

Toll-like receptor

P932

2719935

http://www.w3.org/2001/XMLSchema#string